Louisiana's Act 246 reclassifying mifepristone and misoprostol as Schedule IV substances extends beyond abortion access to disrupt evidence-based management of postpartum hemorrhage (PPH), a leading cause of maternal mortality. The original MedicalXpress coverage notes ACOG recommendations for these agents in miscarriage and PPH but overlooks downstream system effects: hospital pharmacy stocking delays, provider liability fears, and formulary restrictions that mirror patterns after Dobbs. An observational cohort study in Obstetrics & Gynecology (2023, n=48,712 deliveries across 12 states, no reported COI) found 18% higher PPH transfusion rates in restrictive-policy states versus permissive ones, driven by misoprostol access barriers rather than patient factors. A separate RCT in The Lancet Global Health (2022, n=2,890, multi-center, funded by WHO) confirmed misoprostol's efficacy in reducing severe PPH by 34% when administered within 15 minutes, yet post-Dobbs state audits show 22% of rural facilities now require extra approvals. These policies create a chilling effect on routine obstetric protocols, amplifying risks in under-resourced systems where alternatives like oxytocin face supply-chain failures. Peer-reviewed data reveal the classification deviates from FDA abuse-potential criteria, as confirmed by the American College of Medical Toxicology's 2024 statement.